Stock Ratings / Health Care / VMD / dividends

AGL (37) PARK (56) PGNY (78) CCEL (70) ⌘ Pro Terminal →

Viemed Healthcare Inc. (VMD) Dividend Safety Gauge & 10-Year DRIP Compounder

$9.67 -2.81% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $9.64

Viemed Healthcare Inc. (VMD) earns a Roarable Rating of B (Buy) with 75/100 RQD Confidence. High-quality cash engine (58% profit margin, 13% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 75/100 (B) historically ranked in the Top 12% of excess returns over the next 90 days (+7.4% avg 90D alpha vs SPY • 69.7% hit rate) →

ROARABLE B • BUY Cap $379.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on VMD Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is VMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Viemed Healthcare Inc. (NASDAQ: VMD) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 75/100 at a spot price of $9.67 (-2.81% 1D, market cap $379.0M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, VMD ranks #44 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does VMD compare to AGL and PARK in the Health Care sector?

▼

Within the Health Care sector (Misc Health and Biotechnology Services), VMD carries a Roarable B (75/100 RQD), trailing P/E of 24.6x, gross margin of 57.5%, and ROIC of 13.0%. By comparison, AGL (agilon health inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $1.44B) and PARK (Park Dental Partners Inc.) posts a D+ grade (56/100 RQD, P/E N/A, ROIC —, cap $95.4M). Among the 5-stock peer group, VMD leads on earnings multiple (24.6x) while CCEL leads on capital efficiency (18.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for VMD?

▼

Per VMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001729149), Viemed Healthcare Inc. generated $270.3M in revenue (+20.5% YoY), $15.4M in net income, and $11.9M in free cash flow against $199.2M in total assets and $11.3M in total debt. Key quantitative strengths: Strong cash generator (58% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $9.64 (-0.27%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 4.4% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 75/100 (B) historically ranked in the Top 12% of excess returns over the next 90 days (+7.4% avg 90D alpha vs SPY • 69.7% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B

3-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B · Rk B+

Each axis scored 0–20

12M PRICE TARGET CONE+7.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VMD)Realized 20D OHLCV Swing Band: ±5.6%

Deterministic 5-Pillar Attribution (75/100 Composite)

🔍 WHY VMD SCORES 75/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (24% of score)

Altman Z-Score 6.59 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9

▲ #2 Bullish Driver: Cash Engine Quality+16/20 pts (21% of score)

SEC XBRL FY 2025 (10-K): 4.4% FCF Margin ($11.9M FCF) & 57.5% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning12/20 pts (-8 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-8 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B-$9.60-0.1% Next Q

Q2 (-2Q)

Grade B$9.59+1.5% Next Q

Q3 (-1Q)

Grade B$9.73-0.6% Next Q

Current

Grade B$9.67+7.4% Hist 90D α

Trajectory: B- (67) → B (75)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the VMD Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 75/100 (B) score, VMD faces multiple-compression risk if 24.6x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 55.0% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($9.25) or 200D SMA ($9.58) invalidates the momentum regime and cuts Target Base ($10.41) toward Bear Floor ($7.93).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $VMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “VMD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 75%NO 25%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (13.1% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $34,247

Est. Year-10 Shareholder Yield: $616/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$11.3K

Yr 1

$12.8K

Yr 2

$14.5K

Yr 3

$16.4K

Yr 4

$18.5K

Yr 5

$20.9K

Yr 6

$23.7K

Yr 7

$26.8K

Yr 8

$30.3K

Yr 9

$34.2K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Cash-Flow & Quality Compounder Desk

Cash-Fortress Compounders: Auditing Free Cash Flow & Yield Safety in VMD & A-Rated Leaders

✓12-month Bull/Base/Bear fair-value walkthrough on VMD and its top sector peer
✓Top Roarable A-Rated cash compounders with verified executive & 13F accumulation
✓Includes nightly RQD rating-change & forensic signal email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

VMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +2.00%📐 HORIZONTAL RANGE

2026-11-02O $9.99H $9.99L $9.67C $9.67VOL 227.3K

RES: $10.25SUP: $8.62SMA50: $9.25SMA200: $9.58

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

VMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 VMD Butterfly Map → + Track VMD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

18.3%/yr Implied 5Y Growth

vs. +20.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on VMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for VMD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for VMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VMD)

Health Care Rank #44 of 1016 ⚔️ AGL vs VMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (VMD vs. AGL, PARK, PGNY, CCEL)

Industry: Misc Health and Biotechnology Services (10 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Viemed Healthcare Inc. (VMD) ranks #44 by composite RQD confidence (75/100, grade B) and #487 by equity capitalization ($379.0M). Within this direct 5-issuer industry benchmark cohort, VMD leads on earnings valuation at 24.6x trailing P/E, while CCEL leads on capital efficiency and profitability with 18.2% ROIC and — gross margin. PGNY currently holds the highest overall quantitative score in the immediate peer group at 78/100 (B+) compared with VMD at 75/100 (B).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
VMD ACTIVE Viemed Healthcare Inc.	B	75/100	24.6x	57.5%	13.0%	-2.81%	$379.0M	Benchmark Subject
AGL agilon health inc.	D-	37/100	—	—	-35.0%	-1.21%	$1.44B	/agl-vs-vmd →
PARK Park Dental Partners Inc.	D+	56/100	—	—	—	+5.14%	$95.4M	/park-vs-vmd →
PGNY Progyny Inc.	B+	78/100	37.2x	23.6%	16.7%	+2.78%	$2.18B	/pgny-vs-vmd →
CCEL Cryo-Cell International Inc.	B-	70/100	—	—	18.2%	+0.48%	$41.8M	/ccel-vs-vmd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001729149

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Viemed Healthcare Inc. (VMD) reported GAAP revenue of $270.3M (+20.5% vs. FY2024 revenue of $224.3M , and +47.7% cumulative change since FY2023) , GAAP net income of $15.4M, operating cash flow of $51.9M, and free cash flow of $11.9M (+805.2% YoY). On the balance sheet, VMD closed FY2025 with $199.2M in total assets against $11.3M in total debt (Altman Z-Score: 6.59, Piotroski F-Score: 9/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$270.3M	$15.4M	$51.9M	$11.9M	$199.2M	$11.3M
FY2024 (FY)	2024-12-31	$224.3M	$11.4M	$39.1M	$1.3M	$177.1M	$3.6M
FY2023 (FY)	2023-12-31	$183.0M	$10.2M	$45.2M	$45.2M	—	—

3. VMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is VMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does VMD compare to AGL and PARK in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for VMD?

Where is VMD trading relative to its 50-day, 200-day, and 52-week technical levels?

VMD last traded at $9.67 (-2.81% on volume of 119,544 shares), positioning the stock +4.54% above its 50-day simple moving average ($9.25) and +0.94% above its 200-day simple moving average ($9.58). Across its 52-week range of $6.05 to $12.61, VMD sits at the 55.2% percentile with a 14-day RSI of 60.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±5.6% ($9.13 to $10.21).

VMD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does VMD pay a dividend and is it safe?

Viemed Healthcare Inc. (VMD) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: VMD RQD Cockpit VMD 12M Forecast VMD Earnings & Move VMD Dividends & DRIP VMD Insiders & 13F VMD Whale Options VMD Profit Sankey VMD News & Why